Prescription drug monitoring programs

Prescription drug monitoring programs (PMPs) are systems through which clinicians can check a patient’s prescription records, in part to identify doctor-shopping. In Dopesick, they occupy a contested middle ground: Purdue Pharma promoted a state monitoring program as one element of its response to OxyContin abuse, while bereaved families pressed for monitoring as a public safeguard. The programs could make prescribing more visible, but they were not a substitute for treatment or a solution to the conditions that made care difficult to reach.

Purpose and Policy Context

A PMP gives doctors a way to consult a patient’s prescription history and recognize whether prescriptions may be coming from multiple sources. The book presents this function against the rapid expansion of opioid prescribing. OxyContin’s 1996 introduction coincided with a medical shift that treated pain as the fifth vital sign. New standards for pain assessment and treatment, alongside patient-satisfaction surveys that affected hospital competition and reimbursement, encouraged liberal pain treatment. Purdue Pharma promoted OxyContin for a broad range of pain and told clinicians that addiction was rare. These developments form the prescribing environment in which monitoring programs became a proposed check; the text does not present PMPs as the cause of the epidemic or as a remedy for the wider prescribing system.

Purdue Pharma’s Ten-Point Response

In April 2001, after the Drug Enforcement Administration asked Purdue Pharma to limit OxyContin distribution, rethink its marketing, and consider an abuse-resistant formulation, the company announced a ten-point plan to curb abuse. The plan included tamper-resistant prescription pads, an educational program about prescription-drug dangers for teenagers, and a $100,000 grant to create a statewide PMP intended to halt doctor-shopping. The company also stopped distributing its 160-milligram tablet and reduced shipments to Mexico amid reports that OxyContin was being smuggled back into the United States.

The monitoring grant therefore appeared within a package that combined prescription oversight, public education, and changes to supply. It also came from the company whose marketing had helped expand the drug’s use. That dual role matters to the book’s account: a monitoring system could help clinicians see prescription patterns, while Purdue’s response did not resolve the dispute over the drug’s risks, its promotion, or the scale of its distribution.

Activists Make Monitoring a Public Demand

Prescription monitoring became a sustained goal for families who had lost children to OxyContin. Ed Bisch and Lee Nuss, both bereaved parents, joined with Art Van Zee and Sister Beth Davies in an informal alliance that developed into Relatives Against Purdue Pharma. The group lobbied for statewide PMPs so doctors could check prescription records and guard against patients obtaining prescriptions from multiple providers. Members also held school drug-prevention workshops and demonstrated outside Purdue Pharma’s headquarters with large photographs of their dead children.

For these activists, monitoring was one part of a broader campaign, not the whole of it. They repeatedly appeared at public events and in disputes over Purdue Pharma, while also confronting chronic-pain patients who credited OxyContin with helping them function. The book shows how the same drug could be understood through sharply different experiences: a medication that brought relief to some patients and a source of devastating loss to the families seeking tighter controls. PMPs offered a policy demand that could address one mechanism of diversion without settling that conflict.

Funding, Reach, and Limits

The later distribution of Purdue’s $634.5 million fine gave monitoring another institutional role. The money was divided among law enforcement, state and federal Medicaid programs, the creation of Virginia’s Prescription Monitoring Program, and $130 million in civil claims. For Art Van Zee and Sister Beth Davies, the settlement brought satisfaction as well as regret: they objected that the fine did not provide treatment for the medically underserved region that had been disproportionately affected. The Lee County sheriff’s office, meanwhile, received placebo OxyContin pills for use in drug stings. The allocation illustrates the distinction between funding surveillance and meeting local treatment needs.

Elsewhere, the book describes obstacles that a prescription database could not itself remove: cash-only addiction-doctor visits, waiting lists, restrictions on how many patients medication-assisted-treatment doctors could serve, and too few treatment beds. In Roanoke, a five-page spreadsheet listing thirty-six rehabilitation and aftercare providers was an attempt to navigate finances and available beds; during the Hope Initiative’s first month, twenty-two people sought help, but none entered residential treatment. These episodes do not measure the effectiveness of PMPs. They clarify their boundary: tracking prescriptions is an administrative tool, whereas arranging affordable, timely care requires providers, beds, funding, and reliable handoffs. The book’s account leaves monitoring important but incomplete—a way to see prescription activity more clearly, not a path by itself from crisis to recovery.